Well. Veyonda is basically a footnote in this annual report. Recruitment is stalled on DARRT and CEP; IONIC is just dead in the water. The biggest problem was always going to be recruitment and they just can't get these trials moving. They need to be out there hustling to recruit and get some licensing deals, not pissing around with pre-preclinical assets. These other platforms are great, but they are literally years away from human trials.
Ann: Noxopharm 2022 Annual Report, page-2
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $23.37M | |||
| Open | High | Low | Value | Volume |
| 8.2¢ | 8.2¢ | 8.0¢ | $5.491K | 68.10K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 147568 | 8.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.2¢ | 30000 | 1 |
View Market Depth
| Last trade - 14.31pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
8.2¢ |
Change
0.000 ( 5.13 %) |
||||
| Open | High | Low | Volume | ||
| 8.2¢ | 8.2¢ | 8.2¢ | 30000 | ||
| Last updated 11.56am 05/06/2024 ? | |||||
| NOX (ASX) Chart |